2020
JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibition
2018
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
Kim R, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaCTCL cellsBCL2 inhibitionCell lymphomaAdvanced cutaneous T-cell lymphomaHDAC inhibitionSkin-homing T cellsPromising novel therapeutic strategyBET inhibitionNon-Hodgkin lymphomaPotential novel therapyCTCL cell linesDose-dependent decreaseNovel therapeutic strategiesHistone deacetylase inhibitionExtraterminal protein inhibitorSystemic therapyLymph nodesPeripheral bloodNovel therapiesT cellsTherapeutic strategiesCaspase-3/7 activationAdvanced stage
2017
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaB-cell lymphoma 2Advanced cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsHDAC inhibitionT-cell lymphoma patientsNovel BCL2 inhibitorPeripheral blood involvementAvailable systemic therapiesWorse clinical outcomesTreatment of patientsNon-Hodgkin lymphomaT-cell lymphomaCTCL cell linesPotential therapeutic targetHistone deacetylase inhibitionQuality of lifeHistone deacetylase inhibitorsBlood involvementSystemic therapyClinical outcomesTumor burdenLymphoma patientsCombination therapyBCL2 inhibitors
2004
TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.
Kim Y, Girardi M, Duvic M, Kuzel T, Rook A, Link B, Pinter-Brown L, Comerci C, McAuley S, Schmalbach T. TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909. Blood 2004, 104: 743. DOI: 10.1182/blood.v104.11.743.743.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaCPG 7909Progressive diseaseClinical responseStable diseasePartial responseComplete responseAdvanced cutaneous T-cell lymphomaModerate flu-like symptomsGlobal assessmentLocal injection site reactionsCTC grade 1More systemic therapiesObjective clinical responsesPhysician global assessmentDurability of responseFlu-like symptomsInjection site reactionsNK cell functionPhase II portionWeeks of treatmentResults of patientsT-cell lymphomaGamma-glutamyl transferaseImmunomodulator treatment